Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameGolden Throat
Stock Code06896
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是中國領先的潤喉片製造商,旗艦產品金嗓子喉片於1994年推出,另產銷銀杏葉片、金銀三七膠囊及複方百部止咳顆粒等藥品,以及金嗓子喉寶系列食品。
Listing Date2015-07-15
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)廣西壯族自治區柳州市躍進路28號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitegoldenthroat.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 4.60 / shares
Offer Price RangeTo be extracted
Lot Size500 shares
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2015-06-30 to 2015-07-06
Global Offering Shares181,590,000 shares
HK Public Offer Shares (Initial)18,159,000 shares (10.0%)
Public Offer Lots (Initial)36,318lots (Pool A18,159lots,Pool B18,159lots)
International Placing Shares (Initial)163,431,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO726,360,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share9.3%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 835,314,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 2.07B
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +369%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣121.7百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201220132014
Revenue 587,802548,857606,801
Cost of sales -210,185-181,994-176,893
Gross profit 377,617366,863429,908
Other income and gains, net 14,66815,76618,250
Selling and distribution expenses -200,258-230,110-213,286
Administrative expenses -53,470-47,674-59,101
Operating profit 136,47497,969170,376
Net finance costs -7,972-5,726-13,538
Profit before tax 128,50292,243156,838
Income tax expense -25,658-22,325-35,128
Profit for the year 102,84469,918121,710
Profit attributable to owners 102,84469,918121,893
Balance Sheet
Item 201220132014
Cash and cash equivalents 105,702145,505127,163
Trade and bills receivables 296,705300,996261,998
Inventories 85,79048,31947,853
Total current assets 576,185509,608495,866
Total assets 645,418590,726568,026
Total current liabilities 206,811419,477471,997
Total liabilities 211,087423,713476,674
Total equity 434,331167,01391,352
Equity attributable to owners 434,331167,01391,352
Income Statement
Balance Sheet
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 4.87
First Day OpenHK$ 4.71
First Day Change5.87%
First Day Volume22025000.0
First Day Turnover107332000.0
Use of Proceeds
1、約23%(或175.9百萬港元)將用于興建位于廣西壯族自治區柳州市洛維工業集中區或替代土地的新藥品生產及研發基地; 2、約21%(或160.6百萬港元)將用于將我們現時位于廣西壯族自治區柳州市躍進路28號的總部改造成食品生產廠房及食品研發中心; 3、約32%(或244.7百萬港元)將用于2015年、2016年及2017年的市場擴展; 4、約9%(或68.8百萬港元)將用于產品開發; 5、約4%(或30.6百萬港元)將用于在我們現時位于廣西壯族自治區來賓市的場地建立中草藥加工基地; 6、約1%(或7.6百萬港元)將用于改進及升級我們的電子追蹤碼系統以更好地監控我們藥品及食品的分銷; 7、余下約10%的款項(或76.5百萬港元)將用作我們的營運資金及其他一般公司用途。

Underwriting Syndicate

Sole Sponsor (1)
Credit Suisse (Hong Kong) Limited CE AAO017
Overall Coordinators (1)
Credit Suisse (Hong Kong) Limited CE AAO017
Joint Bookrunners (1)
Credit Suisse (Hong Kong) Limited CE AAO017
Joint Lead Managers (1)
Credit Suisse (Hong Kong) Limited CE AAO017

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Super Silverwood Limited 155,999,800 HKD — 4.70% — 6 months 2016-01-15
2 广州润钿营销策划有限公司 77,999,900 HKD — 2.30% — 6 months 2016-01-15
3 康健企业咨询及投资有限公司 46,798,100 HKD — 1.40% — 6 months 2016-01-15
4 中国新锐医药控股有限公司 31,199,500 HKD — 0.90% — 6 months 2016-01-15

Directors & Management

PositionChinese nameEnglish Name
Chairman江佩珍—
Company Secretary吳詠珊—
No director data available.

Major Shareholders

Major Shareholders & Holdings曾勇先生透過家族信託、僱員信託及高級管理層信託控制緊接全球發售前全部已發行股本,緊隨全球發售後被視為持有已發行股本約75.0%;家族信託持有448,516,800股,佔約61.7%;江佩珍女士被視為持有96,253,200股,佔約13.3%。
About this page

This page shows Golden Throat (06896) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect